A 6-month open-label extension study of the safety and efficacy of subcutaneous belimumab in patients with systemic lupus erythematosus

OBJECTIVE: To evaluate the safety, tolerability and efficacy of subcutaneous (SC) belimumab in patients with systemic lupus erythematosus (SLE) beyond 1 year. METHODS: This was a 24-week, open-label extension following a 52-week, double-blind, placebo-controlled trial of belimumab SC. Patients who c...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Lupus
Main Authors: Doria, A, Bass, D, Schwarting, A, Hammer, A, Gordon, D, Scheinberg, M, Fox, N L, Groark, J, Stohl, W, Kleoudis, C, Roth, D
Formato: Artigo
Idioma:Inglês
Publicado: SAGE Publications 2018
Assuntos:
Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6066857/
https://ncbi.nlm.nih.gov/pubmed/29807477
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0961203318777634
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares